Related Experiment Video
Updated: May 28, 2026

Metabolic Glycoengineering of Sialic Acid Using N-acyl-modified Mannosamines
Published on: November 25, 2017
Discovery of a new class of glucosylceramide synthase inhibitors
Elena Koltun1, Steven Richards, Vicky Chan
1Exelixis, 210 E. Grand Avenue, South San Francisco, CA 94005, USA.
Abstract:
A novel series of potent inhibitors of glucosylceramide synthase are described. The optimization of biochemical and cellular potency as well as ADME properties led to compound 23c. Broad tissue distribution was obtained following oral administration to mice. Thus 23c could be another useful tool compound for studying the effects of GCS inhibition in vitro and in vivo.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Sulfonylureas
Dipeptidyl Peptidase 4 Inhibitors
Inhibitors of Gram-positive Cell Wall Synthesis
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Glinides

